摘要
目的:研究阿托伐他汀联合磷酸肌酸钠(CP)对非缺血性心衰(NIHF)的疗效。方法:于我院治疗的120例慢性NIHF患者被随机均分为CP组、阿托伐他汀组与联合治疗组(常规治疗基础上加用CP联合阿托伐他汀),三组均治疗15d。比较三组治疗前后血清NT-proBNP、可溶性生长刺激表达基因2蛋白(sST2)、hsCRP水平、LVEF、LVEDd、LVESd、6min步行距离(6MWD)及治疗总有效率、不良反应发生率。结果:与CP组治疗后比较,阿托伐他汀组血清hsCRP水平显著升高[(13.01±0.36)mg/L比(14.31±0.38)mg/L,P=0.001]。与CP组、阿托伐他汀组治疗后比较,联合治疗组血清NT-proBNP[(2256.67±546.39)pg/ml比(2347.10±553.21)pg/ml比(981.10±353.21)pg/ml]、sST2[(29.42±5.24)ng/ml比(29.31±5.31)ng/ml比(25.31±5.31)ng/ml]、hsCRP水平[(9.31±0.38)mg/L]、LVEDd[(58.13±2.27)mm比(58.20±2.33)mm比(50.10±3.20)mm]、LVESd[(44.28±2.03)mm比(45.18±2.17)mm比(39.30±5.31)mm]均显著降低,LVEF[(36.10±1.64)%比(36.75±2.49)%比(42.36±1.03)%]、6MWD[(273.25±70.46)m比(268.48±71.27)m比(336.33±89.14)m]均显著升高,P均<0.01。联合治疗组治疗总有效率显著高于CP组与阿托伐他汀组(75.00%比45.00%比30.00%,P均<0.01),三组不良反应发生率无显著差异(P=0.875)。结论:阿托伐他汀联合磷酸肌酸钠可显著降低非缺血性心衰患者血清NT-proBNP、sST2、hsCRP水平,改善心功能,疗效显著且安全性高。
Objective:To study therapeutic effect of atorvastatin combined creatine phosphate sodium(CP)on patients with non-ischemic heart failure(NIHF).Methods:A total of 120 chronic NIHF patients treated in our hospital were randomly and equally divided into CP group,atorvastatin group and combined treatment group(received CP combined atorvastatin based on routine treatment).All groups were treated for 15d.Serum levels of NT-proBNP,soluble growth stimulation expressed gene 2(sST2)and hsCRP,LVEF,LVEDd,LVESd and 6-min walking distance(6MWD)before and after treatment,total effective rate and incidence rate of adverse reactions were compared among all groups.Results:Compared with CP group after treatment,there was significant rise in serum hsCRP level[(13.01±0.36)mg/L vs.(14.31±0.38)mg/L]in atorvastatin group,P=0.001.Compared with CP group and atorvastatin group after treatment,there were significant reductions in serum levels of NT-proBNP[(2256.67±546.39)pg/ml vs.(2347.10±553.21)pg/ml vs.(981.10±353.21)pg/ml],sST2[(29.42±5.24)ng/ml vs.(29.31±5.31)ng/ml vs.(25.31±5.31)ng/ml]and hsCRP[(9.31±0.38)mg/L],LVEDd[(58.13±2.27)mm vs.(58.20±2.33)mm vs.(50.10±3.20)mm]and LVESd[(44.28±2.03)mm vs.(45.18±2.17)mm vs.(39.30±5.31)mm],and significant rise in LVEF[(36.10±1.64)%vs.(36.75±2.49)%vs.(42.36±1.03)%]and 6MWD[(273.25±70.46)m vs.(268.48±71.27)m vs.(336.33±89.14)m]in combined treatment group,P<0.01 all.Total effective rate of combined treatment group was significantly higher than those of CP group and atorvastatin group(75.00%vs.45.00%vs.30.00%,P<0.01 both),and there were no significant difference in incidence rate of adverse reactions among three groups(P=0.875).Conclusion:Atorvastatin combined creatine phosphate sodium can significantly reduce serum levels of NT-proBNP,sST2 and hsCRP,and improve cardiac function with significant therapeutic effect and high safety in patients with non-ischemic heart failure.
作者
王建飞
史斌浩
李陈璇
WANG Jian-fei;SHI Bin-hao;LI Chen-xuan(Department of Cardiology,Second People's Hospital of Anhui Province,Hefei,Anhui,230041,China)
出处
《心血管康复医学杂志》
CAS
2022年第6期698-703,共6页
Chinese Journal of Cardiovascular Rehabilitation Medicine
基金
2020年度安徽省高校自然科学研究(2020ZR12925B006)。
关键词
心力衰竭
磷酸肌酸钠
阿托伐他汀
Heart failure
Creatine Phosphate Sodium
Atorvastatin
